marked.bio

MEK inhibitor · small molecule

atebimetinib

1 active trials across 3 of our biomarkers, targeting MEK1/2. Not approved for any biomarker on marked.bio yet.

Also known as IMM-1-104.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 1/2
KRAS G12C 1 1 Phase 1/2
KRAS G12D 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of atebimetinib.

  1. Immuneering 1

Trials

1 of 1 trials shown

  1. A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Immuneering Started 2022Primary completion 2027-06 NCT05585320

    atebimetinibgemcitabinenab-paclitaxelFOLFIRINOXdabrafenibpembrolizumab

    …sectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)

    KRAS G12CKRAS G12DBRAF V600EAdvanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)